Back to top

TG Therapeutics price target raised to $20 from $17 at BofA

BofA analyst Alec Stranahan raised the firm’s price target on TG Therapeutics (TGTX) to $20 from $17 and keeps an Underperform rating on the shares...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

TG Therapeutics, Inc. (TGTX)